145 related articles for article (PubMed ID: 38065967)
21. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
22. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
[TBL] [Abstract][Full Text] [Related]
23. Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
Mian H; Reece D; Masih-Khan E; McCurdy A; Kardjadj M; Jimenez-Zepeda VH; Song K; Louzada M; LeBlanc R; Sebag M; White D; Stakiw J; Reiman A; Kotb R; Aslam M; Gul E; Venner CP
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):608-617. PubMed ID: 35379589
[TBL] [Abstract][Full Text] [Related]
24. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lonial S; Popat R; Hulin C; Jagannath S; Oriol A; Richardson PG; Facon T; Weisel K; Larsen JT; Minnema MC; Abdallah AO; Badros AZ; Knop S; Stadtmauer EA; Cheng Y; Amatangelo M; Chen M; Nguyen TV; Amin A; Peluso T; van de Donk NWCJ
Lancet Haematol; 2022 Nov; 9(11):e822-e832. PubMed ID: 36209764
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
[TBL] [Abstract][Full Text] [Related]
26. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
[TBL] [Abstract][Full Text] [Related]
27. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
28. Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy.
Brechbühl S; Bacher U; Jeker B; Pabst T
Mediterr J Hematol Infect Dis; 2021; 13(1):e2021012. PubMed ID: 33489051
[TBL] [Abstract][Full Text] [Related]
29. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
30. Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States.
Varughese P; Smith R; Xue M; Dorrow N; Hogea C; Maiese EM; Buckingham T
Expert Rev Hematol; 2023 Jan; 16(1):65-74. PubMed ID: 36579455
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
32. Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies.
Kikuchi T; Tsukada N; Kunisada K; Nomura-Yogo M; Oda Y; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Ishida T
Ann Hematol; 2023 Dec; 102(12):3489-3497. PubMed ID: 37668787
[TBL] [Abstract][Full Text] [Related]
33. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
Goldsmith SR; Fiala MA; Wang B; Schroeder MA; Wildes TM; Ghobadi A; Stockerl-Goldstein K; Vij R
Ann Hematol; 2020 May; 99(5):1041-1048. PubMed ID: 32130471
[TBL] [Abstract][Full Text] [Related]
34. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Talbot A; Bobin A; Tabone L; Lambert J; Boccaccio C; Deal C; Petillon MO; Allangba O; Agape P; Arnautou P; Belkhir R; Cailleres S; Chaoui D; Chrétien ML; Decaux O; Schulmann S; Frenzel L; Gastaud L; Huart A; Hulin C; Karlin L; Laribi K; Le Calloch R; Lenain P; Macro M; Manier S; Montes L; Moreau S; Moreau P; Morel V; Norwood J; Piocelle FO; Perrot A; Pica GM; Rey P; Schmitt A; Stoppa AM; Tiab M; Touzeau C; Vidal V; Vignon M; Vincent L; Van De Wyngaert Z; Zarnitsky C; Kerbouche N; Paka P; Leleu X; Arnulf B; Avet-Loiseau H; Du Myélome IIF
Haematologica; 2023 Oct; 108(10):2774-2782. PubMed ID: 37078253
[TBL] [Abstract][Full Text] [Related]
35. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.
Kumar S; Durie B; Nahi H; Vij R; Dimopoulos MA; Kastritis E; Terpos E; Leleu X; Beksac M; Goldschmidt H; Hillengass J; Su Z; Hutton B; Cameron C; Khan I; Lam A
Leuk Lymphoma; 2019 Jan; 60(1):163-171. PubMed ID: 29741423
[TBL] [Abstract][Full Text] [Related]
36. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
[TBL] [Abstract][Full Text] [Related]
37. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Schiller GJ; Lipe BC; Bahlis NJ; Tuchman SA; Bensinger WI; Sutherland HJ; Lentzsch S; Baljevic M; White D; Kotb R; Chen CI; Rossi A; Biran N; LeBlanc R; Grosicki S; Martelli M; Gunsilius E; Špička I; Stevens DA; Facon T; Mesa MG; Zhang C; Van Domelen DR; Bentur OS; Gasparetto C
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e286-e296.e4. PubMed ID: 37393120
[TBL] [Abstract][Full Text] [Related]
38. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Rodriguez-Otero P; Sirvent M; González-Rodríguez AP; Lavilla E; de Coca AG; Arguiñano JM; Martí JM; Cabañas V; Motlló C; de Cabo E; Encinas C; Murillo I; Hernández-Rivas JÁ; Pérez-Persona E; Casado F; Sampol A; García R; Blanchard MJ; Anguita M; Lafuente AP; Iñigo B; López A; Ribas P; Arnao M; Maldonado R; Bladé J; Mateos MV; Lahuerta JJ; San Miguel JF
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):413-420. PubMed ID: 33741302
[TBL] [Abstract][Full Text] [Related]
39. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
40. Treatment Options for Triple-class Refractory Multiple Myeloma.
Mikhael J
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):1-7. PubMed ID: 31767529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]